Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Vertex Pharmaceuticals Incorporated's quarterly P/E stands at 27.8x, down 43.0% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 46.1% YoY to 24.4x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 27.74 | 27.77 | 24.37 | 23.31 | 27.89 | 48.68 | 28.76 | 29.00 | — | 24.82 | 27.42 | 21.90 | 24.99 |
| — | -43.0% | -15.3% | -19.6% | — | +96.1% | +4.9% | +32.4% | — | -15.2% | +19.6% | +8.6% | +11.0% | |
| P/S Ratio | 8.95 | 9.58 | 8.99 | 8.20 | 9.72 | 11.35 | 9.01 | 10.95 | 11.43 | 10.15 | 10.54 | 9.12 | 9.19 |
| — | -15.6% | -0.1% | -25.1% | -15.0% | +11.8% | -14.6% | +20.0% | +24.4% | +17.6% | +29.2% | +13.4% | +10.7% | |
| P/B Ratio | 5.87 | 5.91 | 6.22 | 5.83 | 6.71 | 7.63 | 6.39 | 7.77 | 8.19 | 5.88 | 6.04 | 5.49 | 5.92 |
| — | -22.5% | -2.7% | -25.0% | -18.0% | +29.6% | +5.9% | +41.5% | +38.2% | +3.6% | +11.8% | -4.8% | -3.0% | |
| P/FCF | 33.85 | 22.10 | 83.27 | 22.13 | 31.07 | 40.42 | 53.30 | 23.31 | — | 25.78 | 150.36 | 18.45 | 21.31 |
| — | -45.3% | +56.2% | -5.0% | — | +56.7% | -64.5% | +26.3% | — | +7.9% | +736.0% | -11.5% | +27.1% | |
| EV / EBITDA | 21.52 | 24.37 | 21.22 | 19.71 | 23.24 | 45.24 | 23.80 | 25.19 | — | 21.10 | 23.05 | 18.57 | 19.26 |
| — | -46.1% | -10.8% | -21.8% | — | +114.4% | +3.2% | +35.6% | — | -6.1% | +50.8% | +29.4% | +35.4% | |
| EV / EBIT | 22.45 | 24.37 | 22.09 | 18.77 | 21.73 | 41.85 | 22.40 | 23.92 | — | 19.52 | 20.85 | 16.86 | 17.54 |
| — | -41.8% | -1.4% | -21.5% | — | +114.4% | +7.4% | +41.9% | — | -4.1% | +38.5% | +20.2% | +12.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Vertex Pharmaceuticals Incorporated's operating margin was 38.1% in Q1 2026, down 2.2 pp QoQ and up 15.4 pp YoY.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0% | 86.8% | 85.6% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% | 85.9% | 87.3% | 85.4% | 87.2% | 87.6% |
| — | -0.1% | +0.1% | +0.8% | +0.4% | -0.4% | +0.1% | -1.5% | -1.9% | -1.7% | -2.6% | -0.5% | -0.5% | |
| Operating Margin | 39.4% | 38.1% | 40.3% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% | -132.9% | 42.4% | 39.3% | 41.8% | 41.2% |
| — | +67.5% | +14.4% | -4.3% | +129.2% | -46.4% | -10.3% | -3.7% | -422.7% | +29.3% | -12.5% | -13.4% | -18.3% | |
| Net Margin | 32.7% | 34.5% | 36.9% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% | -135.8% | 40.9% | 38.5% | 41.7% | 36.7% |
| — | +48.0% | +17.7% | -6.7% | +125.6% | -43.0% | -18.5% | -9.5% | -469.8% | +38.9% | +8.2% | +4.6% | -0.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.5% | 5.4% | 6.6% | 6.3% | 6.1% | 3.9% | 5.7% | 6.9% | -21.6% | 6.1% | 5.7% | 6.5% | 6.1% |
| — | +38.1% | +16.2% | -8.7% | +128.4% | -35.5% | +0.3% | +6.2% | -452.2% | +23.3% | -6.5% | -13.2% | -13.7% | |
| ROA | 16.2% | 3.9% | 4.7% | 4.4% | 4.4% | 2.8% | 4.1% | 4.9% | -16.3% | 4.7% | 4.4% | 4.9% | 4.7% |
| — | +37.7% | +14.5% | -10.2% | +127.0% | -39.6% | -6.4% | +0.3% | -450.3% | +25.1% | -7.2% | -14.6% | -14.3% | |
| ROIC | 23.0% | 5.1% | 6.2% | 6.4% | 6.3% | 3.5% | 6.0% | 7.2% | -24.8% | 9.4% | 10.5% | 12.7% | 12.8% |
| — | +46.7% | +2.8% | -11.7% | +125.6% | -63.0% | -42.7% | -43.4% | -293.8% | -17.4% | -39.3% | -34.0% | -36.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Vertex Pharmaceuticals Incorporated's Debt/EBITDA ratio is 1.7x, down from 2.9x last quarter — comfortably within a safe range. The current ratio has improved 14.3% YoY to 3.02x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.10 | 0.21 | 0.11 | 0.09 | 0.10 | 0.11 | 0.11 | 0.06 | 0.04 | 0.05 | 0.05 | 0.05 |
| — | +2.6% | +95.1% | -2.8% | +40.8% | +157.0% | +131.9% | +141.6% | +27.3% | -28.9% | -28.9% | -28.7% | -30.1% | |
| Debt / EBITDA | 0.78 | 1.75 | 2.87 | 1.48 | 1.27 | 2.43 | 1.63 | 1.46 | — | 0.60 | 0.77 | 0.69 | 0.72 |
| — | -28.2% | +75.8% | +1.6% | — | +302.0% | +111.4% | +111.2% | — | -37.3% | -8.1% | -2.7% | -3.0% | |
| Current Ratio | 2.90 | 3.02 | 2.90 | 2.36 | 2.52 | 2.65 | 2.69 | 2.47 | 2.52 | 3.50 | 3.99 | 4.08 | 4.14 |
| — | +14.3% | +7.8% | -4.3% | -0.0% | -24.4% | -32.5% | -39.6% | -39.1% | -18.3% | -17.4% | -13.2% | -8.0% | |
| Quick Ratio | 2.46 | 2.57 | 2.46 | 2.00 | 2.16 | 2.29 | 2.35 | 2.20 | 2.26 | 3.29 | 3.78 | 3.89 | 3.96 |
| — | +12.3% | +4.7% | -9.0% | -4.7% | -30.4% | -37.7% | -43.6% | -42.8% | -20.0% | -18.9% | -14.5% | -9.1% | |
| Interest Coverage | 357.95 | — | 394.06 | 394.58 | 347.76 | 244.47 | 406.89 | 164.21 | -341.55 | 123.99 | 109.26 | 109.18 | 104.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying VRTX stock.
Vertex Pharmaceuticals Incorporated's current P/E is 27.7x. The average P/E over the last 4 quarters is 25.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vertex Pharmaceuticals Incorporated's current operating margin is 39.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vertex Pharmaceuticals Incorporated's business trajectory between earnings reports.